Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in alzheimer’s disease patients and in Parkinson’s disease patients

被引：0
|
作者：
S. Genedani
G. Rasio
P. Cortelli
F. Antonelli
D. Guidolin
M. Galantucci
K. Fuxe
L. F. Agnati
机构：
[1] University of Modena and Reggio Emilia,Department of Biomedical Sciences, Section of Pharmacology
[2] Ospedale “Nuovo Montecchi”,Laboratory of Clinical Chemistry
[3] University of Modena and Reggio Emilia,Institute of Clinical Neurology
[4] University of Padova,Department of Human Anatomy and Physiology, Section of Human Anatomy
[5] Karolinska Insitutet,Department of Neuroscience
[6] University of Modena and Reggio Emilia,Department of Biomedical Sciences, Section of Physiology
来源：
Neurotoxicity Research | 2004年 / 6卷
关键词：
Homocysteine; Alzheimer’s disease; Parkinson’s disease; Dehydroepiandrosterone sulphate; Human patients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Homocysteine (HC) and dehydroepiandrosterone sulphate (DHEAS) plasma levels have been evaluated in groups of male and female patients with Parkinson’s Disease (PD) and in a group of female patients with Alzheimer’s Disease (AD) and compared with the corresponding plasma levels observed in a group of age-matched subjects. It has been confirmed that HC plasma levels are enhanced in both PD and AD patients.
引用
收藏
页码：327 / 332
页数：5
相关论文
共 50 条
  • [1] Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients
    Genedani, S
    Rasio, G
    Cortelli, P
    Antonelli, F
    Guidolin, D
    Galantucci, M
    Fuxe, K
    Agnati, LF
    [J]. NEUROTOXICITY RESEARCH, 2004, 6 (04) : 327 - 332
  • [2] Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients
    Martin Nevrly
    Petr Kanovsky
    Hana Vranova
    Katerina Langova
    Petr Hlustik
    [J]. Neurological Sciences, 2010, 31 : 565 - 569
  • [3] Plasma homocysteine levels in pergolide treated Parkinson's disease patients
    Ozkan, S
    Colak, O
    Kutlu, C
    Ertan, M
    Alatas, O
    [J]. MOVEMENT DISORDERS, 2004, 19 : S388 - S389
  • [4] Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients
    Nevrly, Martin
    Kanovsky, Petr
    Vranova, Hana
    Langova, Katerina
    Hlustik, Petr
    [J]. NEUROLOGICAL SCIENCES, 2010, 31 (05) : 565 - 569
  • [5] Lowering homocysteine levels in patients with Alzheimer's disease
    Aisen, P
    Sano, M
    Diaz-Arrastia, R
    Jagust, W
    [J]. DRUG DISCOVERY AND DEVELOPMENT FOR ALZHEIMER'S DISEASE, 2000, 2002, : 225 - 233
  • [6] Evaluation of serum cortisol and dehydroepiandrosterone sulphate levels in Parkinson's disease patients with postural instability
    Gultekin, M.
    Kilic, S.
    Baydemir, R.
    Yuksel, S. Arik
    Yilmaz, S.
    Tanriverdi, F.
    Ilhan, A.
    [J]. MOVEMENT DISORDERS, 2013, 28 : S143 - S143
  • [7] Serum Homocysteine, Dehydroepiandrosterone Sulphate and Lipoprotein (a) in Alzheimer's Disease and Vascular Dementia
    Ray, Lopamudra
    Khemka, Vineet Kumar
    Behera, Prajna
    Bandyopadhyay, Kausik
    Pal, Sandip
    Pal, Keya
    Basu, Debasis
    Chakrabarti, Sasanka
    [J]. AGING AND DISEASE, 2013, 4 (02): : 57 - 64
  • [8] Biomonitoring of mycotoxins in the plasma of patients with Alzheimer's disease and Parkinson's disease
    Souques, Martine
    [J]. ENVIRONNEMENT RISQUES & SANTE, 2022, 21 (03): : 249 - 250
  • [9] Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients
    Nevrly, M.
    Kanovsky, P.
    Vranova, H.
    Langova, K.
    Hlustik, P.
    [J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 (06) : 477 - 478
  • [10] Elevated plasma levels of homocysteine in Parkinson's disease
    Kuhn, W
    Roebroek, R
    Blom, H
    van Oppenraaij, D
    Przuntek, H
    Kretschmer, A
    Büttner, T
    Woitalla, D
    Müller, T
    [J]. EUROPEAN NEUROLOGY, 1998, 40 (04) : 225 - 227
12345